




SUPPLEMENTARY FIGURES AND TABLE



**Supplementary Figure S1: Lipid levels of free fatty acids (FFA), alkyllysophosphatidic acid (alkyl LPA), lysophosphatidic acid (LPA), alkyl phosphatidic acid (alkyl PA) and phosphatidic acid (PA) in cell lysates.** Significantly higher levels of FFA in Farage cells including a 1.7-fold and 1.4-fold ( $P<0.01$ ) increase in oleic acid and arachidonic acid, respectively. Levels of LPA species were elevated by 1.4 to 1.5-fold ( $P<0.05$ ), and levels of alkyl-LPA species were elevated by 1.6 to 1.7 fold ( $P<0.05$ ); C18:0 alkyl-LPA levels were increased by 2.2-fold in Pfeiffer cells ( $P<0.05$ ). C16:0/C18:1 alkyl-PA levels were 2.4-fold higher in Farage cells ( $P<0.001$ ). PA species were 2.2-fold lower in Farage ( $P<0.01$ ) and 1.2 to 4.8-fold lower in Pfeiffer cells ( $P<0.05$ ) compared to LBCL11832. Data from experiment performed in quadruplicates and expressed as fold change compared to LBCL11832. \*  $P<0.05$ , \*\*  $P<0.01$  and \*\*\*  $P<0.001$



**Supplementary Figure S2: In silico analysis of relative gene expression level of endocannabinoid receptor 1 (CNR1).** Cell lines (white bars) are those proliferative upon 2-AG treatment (5-10  $\mu$ M) and cell lines (black bars) are those anti-proliferative upon 2-AG treatment (5-10  $\mu$ M)



**Supplementary Figure S3: Serum effects on the proliferation of DLBCL cell line SUDHL-10 treated with 2-AG.** **A.** DLBCL cell line treated with 2-AG and cultured 4 days in the RPMI medium in the presence of 10% of FBS or CFBS. Data is presented as the percentage of the respective controls without 2-AG. **B.** DLBCL cell line treated with 2-AG and cultured for 4 days in the RPMI medium with 1, 2.5, 5, and 10% of FBS. Data are expressed as mean  $\pm$  SE. \*  $P < 0.05$ , \*\*  $P < 0.01$ , and \*\*\*  $P < 0.001$

**Supplementary Table S1: DLBCL cell lines treated with 2-AG**

<b>Cell lines</b>	<b>Subtype</b>
Pfeiffer	GCB
Sci-1	GCB
SUDHL-10	GCB
WSU-FSCCL	GCB
Farage	GCB
SUDHL-6	GCB
OCI-Ly3	ABC
OCI-Ly10	ABC
OCI-Ly1	GCB
CRL-2261	GCB
WSU-NHL	GCB
OCI-Ly2	GCB
OCI-Ly19	GCB
RCK8	GCB
Ri-1	ABC
SUDHL-4	GCB

GCB, germinal center B cell-like lymphoma; ABC, activated B cell-like lymphoma